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Introduction: Our objective was to evaluate longitudinally the main bone-mass and quality predictors in young
juvenile idiopathic arthritis (JIA) patients by using lumbar spine dual-energy X-ray absorptiometry (DXA) scan, radius
peripheral quantitative computed tomography (pQCT), and phalangeal quantitative ultrasonography (QUS) at the
same time.
Methods: In total, 245 patients (172 females, 73 males; median age, 15.6 years: 148 oligoarticular, 55 polyarticular,
20 systemic, and 22 enthesitis-related-arthritis (ERA) onset) entered the study. Of these, 166 patients were evaluated
longitudinally. Data were compared with two age- and sex-matched control groups.
Results: In comparison with controls, JIA patients, but not with ERA, had a reduced spine bone-mineral apparent
density (BMAD) standard deviation score (P < 0.001) and musculoskeletal deficits, with significantly lower levels of
trabecular bone mineral density (TrabBMD) (P < 0.0001), muscle cross-sectional area (CSA) (P < 0.005), and density-
weighted polar section modulus (SSIp) (P < 0.05). In contrast, JIA showed fat CSA significantly higher than controls
(P < 0.0001). Finally, JIA patients had a significant reduced amplitude-dependent speed of sound (AD-SoS)
(P < 0.001), and QUS z score (P < 0.005).
Longitudinally, we did not find any difference in all JIA patients in comparison with baseline, except for the SSIp
value that normalized. Analyzing the treatments, a significant negative correlation among spine BMAD values,
TrabBMD, AD-SoS, and systemic and/or intraarticular corticosteroids, and a positive correlation among
TNF-α-blocking agents and spine BMAD, TrabBMD, and AD-SoS were observed.
Conclusions: JIA patients have a low bone mass that, after a first increase due to the therapy, does not reach the
normal condition over time. The pronounced bone deficits in JIA are greater than would be expected because of
reduction in muscle cross-sectional area. Thus, bone alterations in JIA likely represent a mixed defect of bone
accrual and lower muscle forces.* Correspondence: falcini@unifi.it
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In juvenile idiopathic arthritis (JIA), a multifactorial re-
duction of bone mineral accrual with impaired bone
mass has been widely reported [1-3]. Chronic inflamma-
tion [4-6], delayed pubertal maturation [3], malnutrition
[7], muscle weakness [6], limited physical activity [8,9],
early onset of JIA [3], and treatments, especially cortico-
steroids [1,10], influence negatively bone mineral density
(BMD) in these subjects. Therefore, although the hered-
ity accounts for a large proportion of variation in BMD,
these factors may exert a significant negative influence
on the development of peak bone mass (PBM) [3,11,12],
with increased fracture risk in adulthood [13,14]. In
addition, JIA patients, after a therapy-induced increase
of BMD, do not seem to reach a normal condition over
time [3].
To assess bone health appropriately, integration between
clinical tools and imaging techniques is required [1,2].
Dual-energy x-ray absorptiometry (DXA) bone measures
are based on a two-dimensional image that precludes
a direct measure of volumetric BMD (vBMD). Because
BMD only partly explains bone quality, these abnormal-
ities may be better estimated by a quantitative assessment
of macro- and microstructural characteristics [15]. Thus,
three-dimensional imaging methods, such as peripheral
quantitative computed tomography (pQCT), allow a se-
lective assessment of both trabecular and cortical bone
and also estimate bone strength [16]. In addition, quantita-
tive ultrasonography (QUS), increasingly used for its low
cost, portability, and lack of exposure to ionizing radiation,
is used to evaluate bone density and structure and also
permits assessment of changes in trabecular and cortical
architecture [16].
Although several studies demonstrated reduced bone
mass or quality in JIA patients [3,6,11,17-21], few large
cross-sectional or prospective, case–control data exist
for children and young adults [3,8,22] and few, in par-
ticular, using DXA, pQCT, and QUS scans simultan-
eously. Thus, the aim of the study was to evaluate bone
mass and quality in children, adolescents, and young
adults with JIA.Methods
Patients were recruited consecutively from the Rheuma-
tology Unit of Florence University between January 2008
and July 2011. All underwent forearm pQCT, QUS scans
at the phalanges, and DXA at the lumbar spine on the
same day.
The study protocol was approved by Hospital Ethics
Committee of Careggi University Hospital of Florence,
and written informed consent was obtained from all
patients and controls or their parents or guardians, as
appropriate.Study population and design
Two hundred forty-five patients (172 female and 73
male patients; median age at study entry, 15.6; range, 9.6
to 28.3 years) fulfilling the criteria for JIA [23] were eval-
uated. One hundred forty-eight had oligoarticular; 55,
polyarticular (rheumatoid factor negative); 20, systemic;
and 22, enthesitis-related arthritis (ERA) onset. Of these,
166 patients (132 females, 34 males; 99 oligoarticular, 30
polyarticular, 18 systemic, and 19 ERA) were followed
up longitudinally with a second DXA, pQCT, and QUS.
Of the oligoarticular patients, 26% had extended arthritis
at the first DXA evaluation, whereas an additional 13%
were so classified at the second evaluation.
For each patient, clinical and demographic data, includ-
ing JIA-type onset, age at diagnosis, disease duration, dis-
ease course, flares, therapy, height, pubertal stage, weight
and body mass index (BMI), and family history of osteo-
porosis, were recorded from medical charts.
Onset of disease was defined as the date on which
arthritis and/or systemic features were documented by a
pediatric rheumatologist [3]. The disease subtype and
the active JIA assessment were defined according to a
previously reported definition [3,23]. Clinical assessment
and laboratory evaluation were performed longitudinally
to report the disease course and flares [3].
Exclusion criteria for both JIA patients and controls
were bone metabolic diseases, hyper-/hypoparathyroid-
ism, hyper-/hypothyroidism, chronic renal failure, can-
cer, pregnancy, lactation, and osteopenia-inducing drugs,
on the basis of the medical history and questionnaires
for osteoporosis risk factors.
Study and laboratory methods
Height was measured by using a wall-mounted stadi-
ometer, and weight was measured to the nearest 0.1 kg.
Age-related reference values of height and BMI (kg/m2)
were obtained from a wide sample of Italian children
[24]. Height and BMI were normalized for chronologic
age by conversion to standard deviation scores (SDSs).
Pubertal staging was carried out according to the Tanner
and Whitehouse criteria [25], and testicular volume was
determined with the Prader orchidometer. The timing of
puberty and the comparison between the normal popula-
tion and JIA patients were assessed [3].
The age at pubertal onset was defined as the age at dur-
able Tanner B2 stage for girls and a testicular volume of
more than 4 ml for boys (G2). The age at which the onset
of puberty occurred was recorded as the average age be-
tween the previous clinic visit, when the child was still
prepubertal, and the clinic visit when the child was G2/B2.
The duration of puberty was recorded as the time from
G2/B2 to G4/B4. The age at G4/B4 was assessed by aver-
aging the ages at the previous clinic visit, when the child
was G3/B3, and the clinic visit when the child was G4/B4.
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BMD was measured at the lumbar spine by dual-energy x-
ray absorptiometry by using the same instrument (Delphi-
A 4500 System; Hologic, Inc., Waltham, MA, USA). All
BMD results were expressed in terms of g/cm2 or BMD Z
scores. Average BMD values for L2 to L4 were used for
calculations.
Because the DXA instrument’s software does not take
into account the actual bone volume strictly related to
body size (weight and height), estimation of the respect-
ive volumetric density (that is, bone mineral apparent
density or BMAD) was determined by using the formula
of Kröger et al. [26], as previously reported [3]:
BMAD ¼ BMDL2‐L4  4= π widthð Þð Þ; expressed in g=cm3:
The Kröger model was validated by using in vivo volu-
metric data obtained from magnetic resonance imaging
of the lumbar vertebrae [27]. The intraobserver coeffi-
cient of variation was 1.0%.
Patients’ BMAD was expressed as Z scores (that is, the
difference between the value of the patient and the nor-
mal value for age divided for standard deviation (SD) of
the normal patients group) to facilitate comparisons be-
tween JIA patients and healthy controls.
Peripheral quantitative computed tomography scan
The left (nondominant) radius was measured by using
pQCT by a single, trained investigator, with a Norland-
Stratec XCT 3000 scanner (Stratec Medical, Pforzheim,
Germany).
Tomographic slices of 2-mm thickness with voxel sizes
of 0.4 mm and a scan speed of 25 mm/sec were taken from
the shaft and the distal part of the radius (66% and 4%
from the distal end plate of the radius, respectively) [28].
Names for end-point variables were chosen according
to the Task Force on Standardization of Bone Structure
and Density Assessment [29] for high-resolution pQCT.
The 4% (distal) radial site allowed assessment of the
trabecular bone to obtain total bone mineral density
(TotBMD, mg/cm3) and trabecular bone mineral density
(TrbBMD, mg/cm3) [28].
For the shaft regions (66%), the analyzed bone traits
were cortical bone mineral density (CrtBMD, mg/cm3),
cortical bone area (CBA, mm2), muscle cross-sectional
area (MuscleCSA, mm2), fat cross-sectional area (FatCSA,
cm2), and density-weighted polar section modulus (SSIp,
mm3, an estimate of bending and torsional bone strength
for cortical bone).
Because growth retardation is common in some JIA
children and adolescents [1,2], all bone size-dependent
parameters (Total, Cortical, and MuscleCSA) were cor-
rected for height.QUS scans
QUS scans were performed with a DBM Sonic 1200 de-
vice (IGEA Bone Profiler, Carpi, Italy), equipped with
two probes mounted on an electronic caliper. With this
technique, we measured (1) amplitude-dependent speed
of sound (AD-SoS, in m/s), the interval between the
start time of the transmitted signal and the time the sig-
nal received reaches the predetermined minimum ampli-
tude value of 2 mV for the first time); and (b) bone
transmission time (BTT, in μsec), the difference between
transmission time in phalanx soft tissue and bone and
transmission time in phalanx soft tissue. AD-SoS and
BTT SDS were automatically generated [16].
Clinical assessment of disease activity
Clinical disease activity was determined as previously de-
scribed [3]. Documentation of patient data included
medical history and physical examination, in particular
the number of active joints, number of joints with lim-
ited range of motion, physician’s global assessment of
disease activity, parent’s/patient’s assessment of overall
well-being (visual analogue scale as part of the Child-
hood Health Assessment Questionnaire [C-HAQ]), and
functional ability (disability as measured in eight do-
mains by the C-HAQ). Patients were categorized as hav-
ing active disease or being in clinical remission for at
least 6 consecutive months, as previously described [3].
Relapse was defined according to the preliminary defin-
ition of disease flare in JIA [3,29].
Type of treatment
During the cross-sectional and longitudinal evaluations,
the following therapies were considered to define the task
of these determinants on spine BMAD values: nonsteroi-
dal antiinflammatory drugs (NSAIDs), sulfasalazine, sys-
temic and intraarticular corticosteroids, methotrexate
(MTX), and TNF-α-blocking agents [3].
For all drugs, the period of administration was also ob-
tained from the outpatient clinic and hospital records at
the time of the first and second evaluations. Moreover,
the number of intraarticular glucocorticoids injections
and the interval between the injection and DXA assess-
ment were noted. Systemic corticosteroid dosages were
converted into a common steroid equivalency (mg/kg
body weight per day of prednisolone-equivalent dose).
Healthy control subjects
At the first evaluation, the control group included 80
healthy age- and sex-matched subjects (58 females, 22
males; median age, 14.8 years; range, 8.9 to 26.7 years),
observed at our medical units for noninflammatory mus-
culoskeletal complaints. At the time of the second scans,
we selected another age- and sex-matched control group
with the same characteristics (82 subjects, 59 females, 23
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The data for part of these groups were also previously
reported [3].
Statistical analysis
Statistical analyses were performed by using SPSSX
(SPSSX Inc., Chicago, IL, USA). Summaries of continuous
variables were given as the means ± SDs or median and
range, depending on whether the data were normally dis-
tributed. Differences between patient groups and controls
were assessed by using the Student t test and Mann–
Whitney U test, depending on the distribution of the ana-
lyzed variable. The χ2 test and the Fisher Exact test were
used as appropriate to examine associations between di-
chotomous variables. Intergroup comparisons for parame-
ters were conducted by using analysis of variance
(ANOVA) or by using repeated-measures analysis of co-
variance (ANCOVA), as appropriate.
Spearman and Pearson correlation tests were used to
determine the correlation coefficients. A multiple step-
wise regression was used to determine the variables thatTable 1 Data for the 141 JIA patients longitudinally evaluated
JIA group
Baseline Second ev
Number of subjects 245 166
Female/male ratio 172:73 132:34
Age, years (range) 15.6 (9.6 - 28.3) 17.1 (11.0
Height, z score −0.6 ± 1.1 −0.5 ± 0.9
BMI, z score −0.3 ± 0.8 −0.1 ± 0.6
Disease duration 5.6 ± 3.2 years 7.2 ± 4.3 ye
C-HAQ DI 0.74 ± 0.63 0.59 ± 0.48
DXA examination
BMC, g 45.17 ± 19.13a 49.04 ± 21
BMAD spine, g/cm2 −0.64 ± 0.80b −0.49 ± 1.1
HR-pQCT
TrbBMD (mg/cm3) 179.5 ± 34.6c 181.9 ± 48
CBA (mm2) 136.3 ± 122. c 149.0 ± 87
CrtBMD (mg/cm3) 1,050.2 ± 126.5 1,079.8 ± 8
Muscle CSA (mm2) 2,112.7 ± 732.4b 2,083.7 ± 6
Fat CSA (mm2) 1,143.1 ± 649.1c 1,110.1 ± 4
SSIp (mm3) 246.3 ± 140.2a 306.8 ± 25
Ultrasonography
-AD-SoS 1,994.5 ± 119.7b 2,003.0 ± 1
-QUS z score −0.6 ± 1.8a −0.5 ± 1.5e
JIA versus controls (transversal study): aP < 0.05; bP < 0.005; cP < 0.0005; JIA versus. co
Controls versus controls (longitudinal study): gP < 0.05; h^^ P < 0.005; iP < 0.0005; JIA
AD-SoS, amplitude-dependent speed of sound; BMAD, bone mineral apparent dens
C-HAQ DI, Childhood Health Assessment Questionnaire Disability Index, range, 0–3
x-ray absorptiometry; FatCSA, fat cross-sectional area; HR-pQCT, high-resolution per
MuscleCSA, muscle cross-sectional area; SSIp, density-weighted polar section modu
density.correlated independently with lumbar spine BMAD, QUS,
and pQCT z scores. P values <0.05 were considered statis-
tically significant.
Results
The general data of the study population and controls
are shown in Table 1.
With respect to exposure to different medications at
study entry, 56% of the JIA patients had received NSAIDs.
Methotrexate had been prescribed to 44.7% and TNF-α-
blocking medications to 22% of patients; 30% had received
sulfasalazine, and glucocorticoids were prescribed to
21.7%. High-dose systemic or oral glucocorticoids had
been administered only to patients with systemic JIA onset
(P < 0.001), whereas the dose administered in the other
JIA subtypes was low, without significant differences
among the different groups. Forty-one percent had taken
glucocorticoids during the year before measurements.
With respect to disease activity, at study entry, 46.1%
of the JIA patients had disease activity, whereas 53.9% of
patients had remission/inactive disease. Our data relatedin comparison to their respective control groups
Control group
aluation Baseline Second evaluation
80 82
58:22 59:23
- 28.9) 14.8 (8.9 - 26.7) 16.9 (10.9 - 28.4)
−0.1 ± 0.9 −0.1 ± 0.7
0.1 ± 0.7 0.2 ± 0.5
ars - -
- -
.56°°°j 51.23 ± 17.90 56.98 ± 16.82h
0°°° 0.24 ± 0.21 0.13 ± 0.32
.8f 217.7 ± 26.3 244.9 ± 28.5i
.6f 209.2 ± 101.3 214.3 ± 74.3
2.1j 1,039.6 ± 79.3 1,078.3 ± 73.1g
97.8f 2,398.5 ± 773.3 2,579.3 ± 794.5h
83.7e 918.3 ± 382.1 945.8 ± 394.2
0.7d,j 284.0 ± 127.9 276.7 ± 110.4
01.1e 2,122.3 ± 113.1 2,152.8 ± 118.9
0.1 ± 1.6 0.2 ± 1.8
ntrols (longitudinal study): dP < 0.05; eP < 0.005; fP < 0.0005.
versus JIA (longitudinal study): j P < 0.05; §j§P < 0.005; §§§ < 0.0005.
ity; BMC, bone mineral content; BMI, body mass index; CBA, cortical bone area;
(0 = best, 3 = worst); CrtBMD, cortical bone-mineral density; DXA, dual-energy
ipheral quantitative computed tomography; JIA, juvenile idiopathic arthritis;
lus; QUS, quantitative ultrasonography; TrbBMD, trabecular bone-mineral
Figure 1 Transversal evaluation. Spine bone mineral apparent density (spine BMAD) SDS (a), trabecular bone mineral density (TrabBMD)
(b), cortical bone mineral density (CrtBMD) (c), cortical bone area ([CBA) (d), muscle cross-sectional area (MuscleCSA) (e), fat cross-sectional area
(FatCSA) (f), density-weighted polar section modulus (SSIp) (g), and Ad-SoS (h) in patients with oligoarticular, polyarticular, systemic, and
enthesitis-arthritis (ERA) JIA versus controls. Bars represent means and 95% confidence intervals. **P < 0.005; ***P < 0.001.
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denced that age was delayed, but not significantly (years
(95% CI)) both in girls (B2, 11.0 ± 2.0 versus 10.5 ± 1.5; B3,
11.8 ± 2.1 versus 11.1 ± 1.7; B4, 12.7 ± 1.9 versus 11.8 ± 1.6)
than in boys (G2, 12.2 ± 2.4 versus 11.6 ± 1.8; G3, 13.4 ±
2.3 versus 12.5 ± 2.1; G4, 14.8 ± 1.7 versus 13.6 ± 1.5).
In the first evaluation, the JIA patients showed re-
duced spine BMAD SDS values in comparison with con-
trols (−0.64 ± 0.80 versus 0.24 ± 0.21; P < 0.001); these
results were also observed when the subjects were di-
vided into oligoarticular (−0.36 ± 0.80; P < 0.005), polyar-
ticular (−0.73 ± 1.01; P < 0.0001), and systemic (−1.34 ±
1.20; P < 0.0001) onset groups. Conversely, ERA subjects
did not show any difference in comparison to controls
(0.01 ± 0.52; P =NS) (Figure 1a).
In addition, significant musculoskeletal deficits were ob-
served at the time of the first evaluation. The JIA patients
had significantly lower levels of TrbBMD than did controls
(179.5 ± 34.6 versus 217.7 ± 26.3 mg/cm3; P < 0.0001).
These results were also observed when the subjects were
divided into oligoarticular (191.9 ± 43.2, P < 0.05), polyarti-
cular (172.5 ± 55.5, P < 0.0001), and systemic onset (157.6 ±
39.3, P < 0.0001) groups, but not in the ERA group
(209.6 ± 44.4, P = NS) (Figure 1b).
In contrast, the JIA patients did not show significant dif-
ferences in CrtBMD (Figure 1c) in comparison to the
controls (1,050.2 ± 126.5 versus 1,039.6 ± 79.3, P =NS),
even if we considered the different subtypes (oligoarticular,
1,057.5 ± 142.4; polyarticular, 1,068.1 ± 76.8; ERA, 1070.4 ±
71.2 mg/cm3), except systemic-onset patients, who had a
significant reduction (994.0 ± 87.3 mg/cm3, P < 0.0001). At
the same time, cortical bone area, CBA (Figure 1d), ap-
peared significantly reduced in comparison to controls
(136.3 ± 122.1 versus 209.2 ± 101.3 mm2; P < 0.0001), even
if the subjects were divided into oligoarticular- (148.5 ±
112.0 mm2, P < 0.0001), and systemic-onset (126.3 ±
49.0 mm2, P < 0.0001) groups, but not when comparing
the controls with the polyarticular (186.3 ± 131.1 mm2,
P =NS) and ERA (187.5 ± 64.5 mm2, P =NS) groups.
The JIA patients also showed significantly lower
muscle CSA (Figure 1e) than did controls (2,112.7 ±
732.4 versus 2,398.5 ± 773.3 mm2, P < 0.005). These dif-
ferences relative to the controls were also confirmed in
the polyarticular (2,100.5 ± 764.4 mm2, P < 0.001) and
systemic-onset (2,023.2 ± 632.8 mm2, P < 0.0001) groups,
but not in the oligoarticular (2,167.7 ± 870.2, P =NS) and
ERA (2,420.2 ± 973.1 mm2, P =NS) groups.
Fat CSA (Figure 1f) was significantly increased in the
JIA patients relative to the controls (1,143.1 ± 649.1 versus
918.3 ± 382.1 mm2, P < 0.0001), even when the patients
were divided into the different subtypes (oligoarticular,
1,129.6 ± 451.0 mm2; polyarticular, 1,080.9 ± 504.8 mm2;
systemic, 1,139.7 ± 351.9 mm2; ERA, 1,335.2 ± 748.2 mm2,
P < 0.0001).The JIA patients also had significantly lower SSIp levels
(Figure 1g) than controls (246.3 ± 140.2 versus 284.0 ±
127.9 mm3, P < 0.05), even when divided into polyarti-
cular (220.2 ± 82.9, P < 0.0001) and systemic-onset groups
(228.0 ± 68.6, P < 0.0001), but not when controls were
compared with the oligoarticular group (261.7 ± 134.5,
P =NS). In contrast, subjects with ERA had significantly
increased SSIp values with respect to controls (353.1 ±
129.9, P < 0.05) (Figure 1g).
Finally, in the JIA patients, AD-SoS (Figure 1h) results
were significantly reduced (1,994.5 ± 119.7 versus 2,122.3 ±
113.1 m/s, P < 0.001), even when patients were divided
into subgroups (oligoarticular: 2,004.7 ± 118.6 m/s; polyar-
ticular: 1,992.2 ± 116.2 m/s; systemic: 1,894.3 ± 133.1 m/s;
ERA: 2,003.4 ± 105.8 m/s, P < 0.0001). The results were
comparable also when QUS z-scores in the JIA patients
and controls were evaluated (−0.6 ± 1.8 versus 0.1 ± 1.6,
P = 0.003) and between the subtypes and the controls
(polyarticular: −1.0 ± 1.6; systemic: −2.7 ± 2.0; ERA: −0.8 ±
1.5, P < 0.0001), except for the oligoarticular-onset subtype
(−0.4 ± 1.7, P =NS).
The correlations among the variables in the transversal
study are reported in Tables 2 and 3.
Longitudinal evaluation
At the time of the second evaluation, the median chro-
nologic age was 17.7 years (range, 10.2 to 29.6 years). At
this time, disease duration was 7.2 ± 4.3 years, and mean
disease activity, 2.8 years. Disease duration was not sig-
nificantly different among the subgroups of patients
(Table 1). Besides, at longitudinal evaluation, 42.2% of
the JIA patients had active disease, whereas 57.8% of pa-
tients had remission/inactive disease.
The longitudinal evaluation confirmed that the JIA pa-
tients had a reduced spine BMAD SDS in comparison
with controls (−0.49 ± 1.10 versus 0.13 ± 0.32; P < 0.001).
These results were still observed when the subjects were
divided into oligoarticular (−0.29 ± 1.13; P < 0.005), polyar-
ticular (−0.55 ± 1.24; P < 0.0001), and systemic subtypes
(−1.36 ± 1.33; P < 0.0001), but not in the ERA subtype
(0.05 ± 0.71; P =NS) (Figure 2a). Evaluating the differences
among the JIA subgroups, oligoarticular (−0.36 ± 0.80 ver-
sus -0.29 ± 1.11), polyarticular (−0.73 ± 1.01 versus -0.55 ±
1.23), and ERA (0.01 ± 0.52 versus 0.05 ± 0.71; P =NS); no
differences with respect to the findings in the first evalu-
ation were noted, except for patients with systemic onset
(−1.34 ± 1.20 versus -1.46 ± 1.44; P < 0.0001).
The JIA patients were confirmed to have significantly
lower levels of TrbBMD (Figure 2b) than controls
(181.9 ± 48.8 versus 244.9 ± 28.5 mg/cm3, P < 0.0001).
These results were observed also in the oligoarticular
(190.6 ± 44.7, P < 0.0001), polyarticular (169.9 ± 46.4, P <
0.0001), systemic (158.1 ± 38.1, P < 0.0001), and ERA
subtypes (210.1 ± 37.4, P < 0.0001). With respect to the
Table 2 Correlation coefficients (rho) between the bone traits in the JIA cohort and controls
pQCT phenotypes DXA Phenotypes QUS phenotypes
TrbBMD CrtBMD Total
density
CBA Bone
area
Muscle
CSA
Fat CSA SSIp BMAD BMD QUS z-
score
AD-SoS BTT
TrbBMD 0.13 0.60*** 0.10 0.14 0.26* 0.16 0.05 0.12 0.12 - 0.05 0.01 0.07
0.19 0.59^^^ 0.23^ 0.19 0.31^^ 0.29^ 0.28^ 0.35^^ 0.15 0.09 0.14 0.18
0.25° 0.78°°° 0.32°° 0.24° 0.35°° −0.10 −0.26° 0.39°° 0.44°° 0.17 0.12 0.31°
CrtBMD 0.34** 0.23* 0.14 0.42*** 0.09 0.36** 0.49** 0.69*** 0.21* 0.60*** 0.64***
0.50^^^ 0.52^^^ 0.28^ 0.39^^ 0.16 0.41^^ 0.46^^ 0.72^^^ 0.22^ 0.70^^^ 0.66^^^
0.39°° 0.83°°° 0.49°° 0.70°°° - 0.27° 0.39°° 0.63°°° 0.80°°° 0.61°°° 0.72°°° 0.82°°°
Tot
density
0.11 0.19 0.41** 0.23 0.22* 0.12 0.46** 0.27* 0.43*** 0.40***
0.39^^ 0.15 0.38^^ −0.20 0.23^ 0.36^^ 0.48^^ 0.24^ 0.50^^ 0.42^^
0.61°°° 0.29° 0.59°°° 0.10 0.32°° 0.24° 0.56°°° 0.18 0.35°° 0.43°°
CBA 0.11 0.22* - 0.26* 0.25* - 0.09 0.28** 0.12 0.24* 0.25*
0.49^^ 0.81^^^ −0.16 0.83^^^ 0.25^ 0.71^^^ 0.31^^ 0.48^^ 0.72^^^
0.82°°° 0.92°°° 0.14 0.42°°° 0.34°° 0.89°°° 0.57°°° 0.26° 0.85°°°
Bone area 0.49** 0.05 0.55** 0.20 0.18 0.05 0.18 0.30**
0.49^^ 0.11 0.66^^ 0.31^^ 0.40^^ 0.09 0.19 0.37^^
0.78°°° 0.37°° 0.72°°° 0.22° 0.75°°° 0.27° 0.47°° 0.71°°°
MuscleCSA - 0.27* 0.47*** 0.53*** 0.66*** 0.15 0.48** 0.76***
−0.37^^ 0.63^^^ 0.42^^ 0.61^^^ 0.13 0.70^^^ 0.80^^^
0.02 0.38°° 0.34°° 0.86°°° 0.19 0.67°°° 0.85°°°
FatCSA −040** 0.11 0.13 - 0.19* - 0.11 - 0.14
−0.48^^ −0.14 0.38^^ −0.05 −0.18 −0.16
0.19 0.37°° 0.39°° −0.22°° −0.43°° −0.31°°
SSIp 0.25* 0.52*** 0.02 0.35** 0.56***
0.21^ 0.53^^^ 0.11 0.31^^ 0.51^^^
0.24° 0.69°°° 0.16 0.53°°° 0.67°°°
BMAD 0.38*** - 0.01 0.16 0.02
0.40^^ 0.21^ 0.28^ 0.19
0.29° 0.39°° 0.57°°° 0.68°°°
BMD 0.31** 0.78*** 0.87***
0.28^ 0.76^^^ 0.72^^^
0.71°° 0.67°°° 0.86°°°
QUS z-
score
0.56*** 0.68***
0.51^^^ 0.59^^^
0.54°°° 0.65°°°
AD-SoS 0.73***
0.68^^^
0.86°°°
The first line of each cell describes the correlation between bone parameters during transversal study of JIA patients; the second line of each cell describes the
correlation between bone parameters during longitudinal study of JIA patients; the third line of each cell describes the correlation between bone parameters
during transversal study of controls.
*JIA transversal study: *P < 0.05; **P < 0.005; ***P < 0.0005; JIA longitudinal study: ^P < 0.05; ^^P < 0.005; ^^^P < 0.0005; °Controls transversal study: °P < 0.05;
°°P < 0.005; °°°P < 0.0005. AD-SoS, amplitude-dependent speed of sound; BTT, bone transmission time. CBA, cortical bone area; CrtBMD, cortical bone mineral
density; FatCSA, fat cross-sectional area; JIA, juvenile idiopathic arthritis; a; MuscleCSA, muscle cross-sectional area; SSIp, density-weighted polar section modulus;
QUS, quantitative ultrasonography; Tot density, total density. TrbBMD, trabecular bone mineral density.
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Table 3 Correlation coefficients (rho) between the bone traits and JIA characteristics in the JIA cohort and controls
Bone
traits
JIA phenotypes
Type at
onset
Age at
onset
Disease
duration
Disease
activity
Flares Chronologic
age
MTX Systemic
corticosteroids
Intraarticular
corticosteroids
Biological
TrbBMD - 0.50** −0.31** -0.24** −0.34** −0.31** 0.05 0.28* −0.56** −0.48** 0.48**
−0.39^^ −0.39^^ −0.43^^ −0.45^^ −0.29^ 0.19 0.32^^ −0.61^^ −0.52^^ 0.39^^
- - - - - 0.74°°° - - - -
CrtBMD 0.08 0.32** 0.24* −0.31** −0.26* 0.64*** −0.28** 0.20 0.26* 0.36**
0.16 0.37^^ 0.28^ −0.28^^ −0.34^^ 0.68^^^ −0.31^^ 0.24^ 0.24^ 0.44^^
- - - - - 0.89°°° - - - -
Tot density −0.11 −0.14 - 0.40*** - 0.44*** -
0.38***
0.28* −0.24* −0.29* −0.26* 0.32**
−0.25^ −0.18 −0.38^^ −0.36^^ −0.42^^ 0.36^^ −0.29^ −0.34^^ −0.28^ 0.46^^
- - - - - 0.62°° - - - -
CBA 0.08 −0.04 −0.18 −0.27* −0.20* 0.46** −0.22* 0.06 0.16 0.39**
0.18 −0.16 −0.21^ −0.31^^ −0.24^ 0.54^^ −0.31^^ 0.14 0.14 0.28^
- - - - - 0.79°°° - - - -
Bone area −0.09 −0.12 −0.23* −0.28* −0.30* 0.09 −0.16 −0.16 −0.14 0.33**
−0.12 −0.19 −0.27^ −0.21^ −0.34^^ 0.10 −0.14 −0.28^ −0.34^^ 0.49^^
- - - - - 0.73°°° - - - -
MuscleCSA −0.26** −0.18 −0.16 −0.41** −0.33** 0.35** −0.17 −0.46** −0.51*** 0.26*
−0.29^^ −0.24^ −0.25^ −0.46^^ −0.38^^ 0.40^^ −0.08 −0.54^^^ −0.56^^^ 0.38^^
- - - - - 0.73°°° - - - -
FatCSA 31.9** 0.34** 0.18 0.35* 0.21* 0.04 0.26* 0.42** 0.26* −0.19
36.6^^ 0.39^^ 0.29^ 0.28^ 0.27^ 0.13 0.39^^ 0.39^^ 0.84^^ −0.31^^
- - - - - 0.23° - - - -
SSIp 0.03 0.09 0.56*** 0.45** 0.38** 0.21* 0.36** 0.51*** 0..46** −0.29*
0.17 0.19 0.48^^ 0.49^^ 0.32^^ 0.23^ 0.34^^ 0.64^^^ 0.39^^ −0.33^^
- - - - - −0.25° - - - -
BMAD - 0.25* 0.48*** −0.34** −0.46*** −0.38** 0.38** - 0.39** - 0.45** - 0.40** 0.43**
−0.23^ 0.52^^^ −0.42^^ −0.51^^^ −0.34^^ 0.47^^ −0,41^^ –0.49^^ −0.43^^ 0.51^^^
- - - - - 0.79°°° - - - -
BMD 0.16 0.34** −0.27* −0.36** −0.27* 0.38** −0.36** −0.53*** −0.41** 0.29*
0.19 0.36^^ −0.32^^ −0.39^^ −0.31^^ 0.58^^ −0.44^^ −0.59^^^ −0.46^^ 0.39^^
- - - - - 0.88°°° - - - -
QUS z-score - 0.25* −0.27* −0.35** −0.41** −0.22* 0.11 0.16 −0.38** −0.36** 0.21*
−0.21^ −0.33^^ −0.39^^ −0.33^^ −0.27^ −0.10 0.12 −0.46^^ −0.44^^ 0.33^^
- - - - - 0.17 - - - -
AD-SoS −0.18 −0.37** −0.51*** −0.39** −0.47** 0.69*** −0.24* −0.59*** −0.57*** 0.61***
−0.23^ −0.42^^ −0.46^^ −0.31^^ −0.32^^ 0.58^^^ −0.38^^ −0.65^^^ −0.51^^^ 0.51^^^
- - - - - 0.71°°° - - - -
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Table 3 Correlation coefficients (rho) between the bone traits and JIA characteristics in the JIA cohort and controls
(Continued)
BTT −0.57*** −0.51*** −0.67*** −0.47** −0.27* 0.43** −0.36* −0.61*** −0.65*** 0.61***
−0.62^^^ −0.64^^^ −0.52^^^ −0.43^^ −0.32^^ 0.66^^ −0.48^^ −0.72^^^ −0.78^^^ 0.67^^^
- - - - - 0.84°°°° - - - -
The first line of each cell describes the correlation between bone parameters and JIA phenotypes during transversal study of JIA patients; the second line of each
cell describes the correlation between bone parameters and JIA phenotypes during longitudinal study of JIA patients; the third line of each cell describes the
correlation between bone parameters during transversal study of controls.
JIA transversal study: *P < 0.05; **P < 0.005; ***P < 0.0005; JIA longitudinal study: ^P < 0.05; ^^P < 0.005; ^^^P < 0.0005; Controls transversal study: °P < 0.05;
°°P < 0.005; °°°P < 0.0005.
AD-SoS, amplitude-dependent speed of sound; BMAD, bone mineral apparent density; BMD, bone mineral density; BTT, bone transmission time; CBA, cortical bone
area; CrtBMD, cortical bone mineral density; FatCSA, fat cross-sectional area; JIA, juvenile idiopathic arthritis; MTX, methotrexate; MuscleCSA, muscle cross-sectional
area; QUS, quantitative ultrasonography; SSIp, density-weighted polar section modulus; TrbBMD, trabecular bone mineral density; Tot density, total density.
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http://arthritis-research.com/content/16/2/R83first examination, we did not find any significant differ-
ences among the JIA patients (181.9 ± 48.8 versus 179.5 ±
58.6 mg/cm3, P =NS), even when they were divided into
oligoarticular (190.6 ± 44.7 versus 191.9 ± 43.2 mg/cm3),
ERA (210.1 ± 37.4 versus 209.6 ± 44.4 mg/cm3), polyarti-
cular (169.9 ± 46.4 versus 172.5 ± 55.5 mg/cm3), and
systemic-onset (158.1 ± 38.1 versus 157.6 ± 39.3 mg/cm3)
subtypes. Conversely, the controls showed a significant in-
crease of TrbBMD with age (244.9 ± 28.5 versus 217.7 ±
26.3 mg/cm3, P < 0.0001).
The JIA patients did not show any significant differences
in CrtBMD (Figure 2c) with respect to controls (1,079.8 ±
82.1 versus 1,078.3 ± 73.1, P = NS), even when differen-
tiated by subtype (oligoarticular: 1,076.7 ± 86.0; polyarti-
cular: 1,066.7 ± 80.6; ERA: 1,077.1 ± 63.2; systemic onset:
1,068.9 ± 39.6 mg/cm3, P < 0.0001). In comparison to the
first examination, a significant increase in CrtBMD for the
JIA patients (1,079.8 ± 82.1 versus 1,050.2 ± 126.5 mg/cm3,
P < 0.05) was observed, although no differences among the
oligoarticular (1,076.7 ± 86.0 versus 1,057.5 ± 142.4 mg/cm3),
polyarticular (1,066.7 ± 80.6 versus 1,068.1 ± 76.8 mg/cm3),
and ERA (1,077.1 ± 63.2 versus 1,070.4 ± 71.2 mg/cm3) sub-
groups were detected; a significant difference was noted
for the systemic-onset subgroup (1,068.9 ± 39.6 versus.
994.0 ± 87.3 mg/cm3, P < 0.0001). The controls showed a
significant increase of CrtBMD with age (1,078.3 ± 73.1
versus 1,039.6 ± 79.3, P < 0.05).
However, the JIA patients’ CBA values (Figure 2d) were
confirmed to be significantly reduced with respect to the
controls (149.0 ± 87.6 vs. 214.3 ± 74.3 mm2, P < 0.0001);
these results were also observed when the subjects were
divided into oligoarticular (149.8 ± 45.0 mm2; P < 0.0001),
polyarticular- (139.46 ± 47.50 mm2, P < 0.0001), and
systemic-onset subgroups (160.5 ± 49.5 mm2; P < 0.005),
but not for the ERA subtype (198.5 ± 69.2 mm2; P =NS).
With respect to the first evaluation, we did not observe
significant differences across all JIA patients (149.0 ± 87.6
versus 136.3 ± 122.1 mm2, P =NS), nor did we observe
such differences for the oligoarticular (149.8 ± 45.0 versus
148.5 ± 112.0 mm2; P =NS), ERA (198.5 ± 69.2 versus
187.5 ± 64.5 mm2, P =NS), and polyarticular (186.3 ± 131.1versus 139.5 ± 47.5 mm2, P = NS) subgroups; however,
the systemic-onset patients (160.5 ± 49.5 versus 126.3 ±
49.0 mm2; P < 0.05) had significantly increased values.
Muscle CSA (Figure 2e) was confirmed to be significantly
reduced in JIA with respect to controls (2,083.7 ± 697.8 ver-
sus 2579.3 ± 794.5 mm2, P < 0.0001). When the patients
were divided into subgroups, we observed a significant dif-
ference in the oligoarticular (2,126.5 ± 711.9, P < 0.0001),
polyarticular (2,146.7 ± 670.7 mm2, P < 0.001), and systemic
(2,056.9 ± 401.0 mm2, P < 0.0001) subtypes but not in the
ERA subtype (2,281.2 ± 887.9 mm2, P =NS). In comparison
to the first examination, we did not observe significant dif-
ferences in the whole group of JIA patients (2,112.7 ± 732.4
versus 2,083.7 ± 697.8 mm2, P =NS) nor in the oligoarticu-
lar (2,126.5 ± 711.9 versus 2,167.7 ± 870, P =NS), polyarti-
cular (2,146.7 ± 670.7 versus 2,100.5 ± 764.4 mm2, P =NS),
systemic-onset (2,056.9 ± 401.0 versus 2,023.2 ± 632.8 mm2,
P = NS), and ERA (2,420.2 ± 973.1 mm2, P = NS) sub-
groups. Conversely, for the controls, we observed a signifi-
cant increase with age (2,579.3 ± 794.5 versus 2,398.5 ±
773.3 mm2, P < 0.001).
Fat CSA (Figure 2f) was still significantly increased in the
JIA patients compared with controls (1,110.1 ± 483.7 versus
945.8 ± 394.2 mm2, P < 0.005), a finding that was similar
for all subtypes (oligoarticular: 1,103.2 ± 489.3 mm2, P <
0.005; polyarticular: 1,099.0 ± 565.2 mm2, P < 0.0001; sys-
temic: 1,255.5 ± 423.1 mm2, P < 0.0001; ERA: 1,289.7 ±
766.8 mm2, P < 0.0001). With respect to the first exa-
mination, we did not find any significant difference for
the whole group of JIA patients (1,110.1 ± 483.7 versus
1,143.1 ± 649.1 mm2, P = NS) nor for any subtype
(oligoarticular: 1,103.2 ± 489.3 versus 1,129.6 ± 451.0, P=NS;
polyarticular: 1,099.0 ± 565.2 versus 1,080.9 ± 504.8 mm2,
P =NS; systemic onset: 1,255.5 ± 423.1 versus 1,139.7 ±
351.9 mm2, P =NS; ERA: 1,289.7 ± 766.8 versus 1,335.2 ±
748.2 mm2, P =NS).
The SSIp longitudinal evaluation (Figure 2g) showed that
the JIA patients had slightly significant lower levels than
the controls (306.8 ± 200.7 versus 276.7 ± 110.4 mm3, P <
0.05), which was also found in the oligoarticular (287.6 ±
178.4, P =NS) and polyarticular subsets (316.1 ± 209.4,
Figure 2 Longitudinal evaluation. Spine bone mineral apparent density (spine BMAD) SDS (a), trabecular bone mineral density (TrabBMD) (b),
cortical bone mineral density (CrtBMD) (c), cortical bone area (CBA) (d), muscle cross-sectional area (MuscleCSA) (e), fat cross-sectional area
(FatCSA) (f), density-weighted polar section modulus [SSIp] (g), and Ad-SoS (h) in patients with oligoarticular, polyarticular, systemic, and
enthesitis-arthritis (ERA) JIA versus controls. Bars represent means and 95% confidence intervals. **P < 0.005; ***P < 0.001.
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(410.4 ± 132.1, P < 0.001) and ERA (374.1 ± 139.1, P <
0.001) had SSIp values significantly increased above those
of the controls (Figure 2). At follow-up, we detected sig-
nificant differences in the JIA patients (306.8 ± 250.7 ver-
sus 246.3 ± 140.2 mm3, P < 0.05), but not in the controls
(276.7 ± 110.4 versus 284.0 ± 127.9 mm3, P =NS). The re-
sults were replicated when JIA patients were divided into
oligoarticular (251.7 ± 144.5 versus 287.6 ± 178.4 mm3,
P =NS) and ERA (374.1 ± 139.1 versus 403.1 ± 189.9 mm3,
P =NS) subgroups, whereas SSIp was significantly in-
creased in the polyarticular- (314.1 ± 329.4 versus 220.2 ±
82.9 mm3, P < 0.05) and systemic-onset (400.4 ± 157.1 ver-
sus 228.0 ± 68.6 mm3, P < 0.001) subgroups.
Finally, longitudinal follow-up showed that AD-SoS
(Figure 2h) remained significantly reduced (2,003.0 ± 101.1
versus 2152.8 ± 118.9 m/s, P < 0.001) in all subtypes of the
JIA patients (oligoarticular: 2,016.1 ± 95.3 m/s; polyarticu-
lar: 1,993.3 ± 108.0 m/s; systemic: 1,897.0 ± 67.7 m/s; ERA:
2,000.4 ± 100.1 m/s, P < 0.0001). With respect to the first
examination, we did not find significant differences for
any JIA subgroups. The results remained comparable
when we evaluated QUS z-scores between the JIA patients
and controls (−0.5 ± 1.5 versus 0.2 ± 1.8, P < 0.005) and be-
tween the subtypes and controls (polyarticular: −0.7 ± 1.5;
systemic: −3.3 ± 1.0; ERA: −0.7 ± 1.4, P < 0.0001); this find-
ing was not replicated for the oligoarticular-onset sub-
group (−0.2 ± 1.3, P =NS). Analyzing the first examination,
we did not find significant differences for any subset of JIA
patients.
The correlations among the variables in the longitu-
dinal study are reported in Tables 2 and 3.
Discussion
This study confirms our previously published data and
further emphasizes that patients with JIA, although cur-
rently effective therapies are available, still manifest im-
paired bone mass and architecture. In addition, these
patients seem not to reach a normal condition over time,
potentially having a high risk of osteoporosis in early
adulthood [3]. This characteristic is especially notable for
children with polyarticular or systemic onset, whereas
those with the oligoarticular and ERA subtypes do not
show low values of BMAD SDS and other bone-density
and quality determinants.
Furthermore, our results show remarkable evidence for
significant musculoskeletal deficits in JIA patients and per-
sistent impaired bone accrual over a period of years,
thereby leading to further reductions of bone mass, in
agreement with previously reported data [1,30,31]. Our
baseline results using pQCT elucidate substantial muscle-
skeletal deficits, partially due to the underlying inflamma-
tion typical of JIA. Nevertheless, our longitudinal data
show that this pattern likely represents the combinedeffects of decreased biomechanical loading by muscle
forces and increased inflammatory cytokines, because only
patients with systemic onset experienced significant ameli-
oration from antiinflammatory treatments.
Indeed, as muscles increase during growth, bones ad-
just by increasing in their dimensions and strength. The
capacity of bone to respond to mechanical loading with
increased bone strength is at its maximum during child-
hood [1]. Numerous studies have demonstrated that
physical activity during childhood promotes cortical
bone acquisition, either because of greater periosteal ex-
pansion or greater endosteal contraction [1,30].
In the last decades, new antirheumatic drugs, such as
methotrexate and anti-TNF-α agents, have radically al-
tered the course and outcome of JIA [32]. Despite these
changes, numerous studies have documented persistent
impaired bone mass and density in the majority of JIA
patients [1,3]. This may suggest that current therapies,
despite improving overall skeletal health, do not support
adequate bone mass with respect to controls across
nearly all JIA subgroups, thereby causing subsequent
osteopenia and osteoporosis [3]. This hypothesis may be
confirmed by the fact that many patients in our study
did not have active arthritis at the time of evaluation.
Thus, bone alterations in JIA likely represent a mixed
defect of bone development and lower muscle strength
[6]. Our data show that young adults with a history of JIA
may be susceptible to deleterious alterations in cortical
bone strength and trabecular bone density, placing them
at greater risk of fracture in the future. To reduce the risk,
close monitoring of BMD, better control of disease activ-
ity, dietary intake of calcium and vitamin D, and especially
greater physical activity may be advocated to support
greater bone mass [3]. Thus, interventions aimed to im-
prove muscle mass and strength may optimize bone
health, resulting in a better PBM.
However, our data provide evidence that children and
adolescents with ERA seem not to have significant re-
ductions in bone mass with respect to controls, although
these patients may have lower levels of physical activity,
poorer physical health, and more bodily pain compared
with oligoarticular or polyarticular subtypes of patients
and controls [33]. So reduced physical activity and re-
duction of muscular mass may not completely explain
these differences between JIA patients and controls and
between patients with ERA and other JIA subgroups. It
is possible that the reduced physical activity may be crit-
ical in conditioning the missed or reduced bone accrual,
whereas the reduction of BMAD, which is frequently
present at diagnosis, may be more related to inflamma-
tion. Limited data are available in the literature regard-
ing bone status in patients with ERA. Burnham et al. [6],
by using pQCT of the left tibia, observed reduced tra-
becular vBMD z-scores in this subtype of JIA.
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spondylitis (AS) seems to occur only in patients with
persistent active disease, strongly suggests that the in-
flammatory activity of the disease itself plays a major
role in the pathophysiology of the early bone mineral
disorders observed in these patients [34]. Disease dur-
ation may also have a role in contributing to impaired
BMD in these patients.
Another concern of our study is the high values of
fatCSA detected in the JIA patients with respect to con-
trols. The link between fat area and BMD remains unclear.
However, recent studies led researchers to hypothesize a
strong relation among leptin, metabolic state, and im-
munologic self-tolerance [35]. Moreover, chronic systemic
inflammation, present in chronic arthritis, has been shown
to increase lipogenesis in nonadipose tissues and lipolysis
in white adipose tissue, resulting in ectopic lipid depos-
ition in nonadipose tissues, such as muscle and liver [36].
The production of proinflammatory cytokines, character-
izing an autoimmune disorder such as SLE, could be asso-
ciated with an increased secretion of leptin and ectopic
lipid accumulation in skeletal muscles, and, conversely,
with higher rates of bone turnover and consequent loss of
bone mass.
Our data also suggest that JIA patients, except for those
with oligoarticular onset, do not experience improvements
in their QUS z-scores with respect to baseline. It has been
postulated that QUS may reflect qualitative aspects of
bone, such as elasticity and microarchitectural characteris-
tics [37] and may potentially be suitable for measuring
several of the various determinants of bone strength [38].
Therefore, although during the follow-up, DXA may show
stable values, the other methods may indicate the con-
trary: a decrease of bone parameters in some JIA sub-
groups, thus better reflecting the evaluation of skeletal
status.
Conclusions
Children with JIA are at risk for deleterious alterations
in cortical bone strength and trabecular bone density,
and consequently, for fractures. In contrast to other
studies, our study demonstrated that the pronounced
bone deficits in JIA are possibly also related to reduc-
tions in muscle cross-sectional area. Thus, bone alter-
ations in JIA likely represent a mixed defect of bone
remodeling and, in some cases, lower muscle forces. Fu-
ture clinical trials assessing bone-active therapies and
mechanical-loading interventions are required.
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